- Home
- / LogicBio Therapeutics
LogicBio Therapeutics
Stock Price
$6.7
2024-10-29
Market Capitalization
$176.3 M
2024-10-29
Revenue
$5.4 M
FY, 2021
LogicBio Therapeutics Summary
Company Summary
- Overview
- LogicBio Therapeutics, a genome editing company, focuses on developing medicines to treat rare diseases in patients with unmet medical need using GeneRide technology platform. The GeneRide technology is designed to integrate corrective genes into a patient's genome to provide a therapeutic effect.
- Type
- Public
- Status
- Active
- Founded
- 2014
- HQ
- Lexington, MA, US | view all locations
- Website
- http://www.logicbio.com/
- Cybersecurity rating
Table of Contents
Key People
Fred Chereau, President, Chief Executive Officer
Mariana Nacht, Chief Scientific Officer
Cecilia Jones, Chief Financial Officer
Operating MetricsView all
Trademarks
2
Q2, 2018
LocationsView all
2 locations detected
Lexington, MA HQ
United States
65 Hayden Ave
Louisville, KY
United States
462 S 4th St
LogicBio Therapeutics Financials
Summary Financials
- Revenue (Q3, 2022)
- $2.7M
- Net income (Q3, 2022)
- ($5.8M)
- Cash (Q3, 2022)
- $30.8M
- EBIT (Q3, 2022)
- ($5.7M)
- Enterprise value
- $155.5M